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Abnormal uterine bleeding is a common gynecological disease and represents one of 
the most frequent reasons for hospital admission to a specialist unit, often requiring 
further surgical treatment. Following the so-called PALM-COEIN system we will 
attempt to further clarify the surgical treatments available today. The first group 
(PALM) is characterized by structural lesions, which may be more appropriately treated 
by means of surgical management. Although hysterectomy remains the definitive 
and decisive choice, there are many alternative techniques available. These minimally 
invasive procedures offer the opportunity for a more conservative approach. Precise 
and accurate counseling facilitates better patient selection, based on the patient’s 
desires, age and disease type, allowing treatment to be individually tailored to each 
woman.
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Abnormal uterine bleeding (AUB) is one 
of the most often encountered gynecologi-
cal disorders in the general population and 
accounts for approximately 400,000 hospital 
admissions. It accounts for millions of office 
visits each year in the USA [1] and 5% of UK 
women aged 30–49 years visit a specialist 
every year for treatment of this disorder [2]. 
Approximately 10–35% of women report 
symptoms of AUB during their lifetime [3].
The impact of AUB is not only limited 
to population-based studies regarding inci-
dence and prevalence, but it directly affects 
quality of life and entails high socioeconomic 
costs.
AUB is a huge entity, comprising different 
symptoms and different etiologies.
It is possible to differentiate between acute 
and chronic AUB disorders [4]. Chronic 
bleeding is characterized by abnormal vol-
ume, regularity and/or timing, with the 
vast majority of patients reporting symp-
toms in the preceding 6 months. Acute AUB 
typically requires immediate treatment [5,6].
Even though the aim of this paper is to 
emphasize the surgical possibilities we have 
for treating AUB, the authors recognize the 
important role of the medical therapies able 
to solve, when possible, in the least invasive 
way, symptoms and causes of AUB.
Surgery often plays an ambiguous role, 
although it may involve an invasive procedure 
and is sometimes considered as last resort, it 
is often more accepted as it provides a defini-
tive treatment option. It is for precisely this 
reason we attempt to clarify the indication 
for surgical management of AUB.
Nowadays, due to increased maternal age 
and the delayed pregnancy desire, it may be 
more common to find women suffering from 
AUB and, at the same time, wishing to pre-
serve their uterus and its functionality to be 
able to conceive. That is the reason why sur-
gical treatment should be highly tailored to 
the patient and should be as less invasive as 
possible. Postoperative pain and symptom 
relief often are considered minor outcomes 
compared with fertility sparing even in cases 
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Figure 1. International Federation of Gynecology and 
Obstetrics PALM-COEIN abnormal uterine bleeding 
basic classification system. 
Reproduced with permission from [4] © Elsevier (2014).
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treated, not so many years ago, with definitive surgi-
cal approach. So the treatment of AUB in fertile age 
women is strictly linked to their fertility preservation 
and their motherhood needs.
AUB is associated with multiple etiologies, the 
terminology of which is often confusing and lacks 
standard methodology for classification and manage-
ment. In 2011 the International Federation of Gyne-
cology and Obstetrics (FIGO) approved a new clas-
sification system, more commonly referred to as the 
PALM-COEIN (Figure 1) [4].
It stands for the major causes of uterine bleeding 
which are divided into nine categories: polyp; adeno-
myosis; leiomyoma; malignancy and hyperplasia; 
coagulopathy; ovulatory dysfunction; endometrial; 
iatrogenic and not yet classified. In the PALM group 
are those causes ascribed to organic/structural anom-
alies, consisting of disease entities more effectively 
treated surgically. The COEIN group, on the other 
hand, consists of disease entities not clearly defined 
by imaging or histopathology, in which surgery plays 
a more minor role, but is still considered a definitive 
choice in case of failed medical treatment.
This new classification system proposes to create a 
novel and practical system, for use by clinicians world-
wide, particularly focusing on the surgical management 
of these disorders.
Following the PALM-COEIN scheme, we attempt 
to evaluate the optimum and most recent surgical 
techniques to treat AUB in fertile women.
As it is outside the scope of this review, we do not 
speak about the diagnostic procedures to evaluate an 
AUB. It is understood that ultrasound scans (included 
hysterosonography), MR and CT examinations, and 
direct vision hysteroscopy play a crucial role. In partic-
ular, we think that examinations based on ultrasound 
technology are the best approach for diagnosis, being 
cheaper than others, with high sensitivity and specificity. 
A good diagnosis is important not only for the patient 
and her consultant, but also for the surgeon, if needed.
Polyps
The first ‘P’ of the classification system stands for 
‘Polyps.’ It is a common gynecological disease and a 
frequent cause of AUB among fertile women. It is esti-
mated that prevalence is around 7.8–34.9% (depend-
ing on the population, the diagnosis method and the 
definition of the polyp) [7–10]. In younger women 
(on whom this review focuses) the prevalence seems 
to be lower than in postmenopausal women (5.8 vs 
11.8%) although there may be an element of bias due 
to improved and more frequent investigation for AUB 
diagnosis among postmenopausal women [8]. The real 
incidence is unclear due to a significant proportion of 
asymptomatic patients with endometrial polyps [11–14]. 
Women with endometrial polyps usually experience 
AUB in 68% of all cases, and 39% of premenopausal 
women with AUB have endometrial polyps [15].
The rationale for the treatment of this disease is 
essentially focused on relieving the symptoms of bleed-
ing, while at the same time, obtaining a histopathologi-
cal diagnosis to exclude rare malignant transformation 
estimated to occur in approximately 0–12.9% [10,16–21] 
of cases, with a higher predisposition for older women 
and those with significantly greater bleeding [22].
The different treatment options available include 
conservative medical management, conservative sur-
gical or definitive surgical management. The choice 
of specific treatment is dependent on factors such as 
symptoms, pregnancy desire, risk of malignancy and 
operator skills.
Polyps with dimensions of around 1 cm can sponta-
neously regress (especially 10.7 mm polyps have a 27% 
chance of spontaneous regression in 12 months [14]), 
so, in these cases, it could be considered an expectant 
approach.
In any case polypectomy appears to be a good 
answer to AUB, with a respectable success rate. A 
review of the literature [23], including 10 studies, 
underlines as all procedures reported an improvement 
in symptoms of AUB (range 75–100%) at follow-up 
intervals of between 2 and 52 months. In particular, 
in the two studies restricted to premenopausal women, 
an improvement in symptomatology between 88 and 
100% was demonstrated [24,25].
For many years the most commonly used tech-
nique was blind dilatation and curettage (D&C) and 
although it is no longer recommended, it still remains 
popular; a survey [26] from the UK in 2002 reported 
that 2% of gynecologists used blind dilation and curet-
tage for the management of endometrial polyps, and 
51% performed blind curettage after hysteroscopy for 
the removal of polyps. This could be due to a difficulty 
in changing habits in the oldest surgeons or in those 
who learn by them. Many studies have highlighted the 
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inefficiency of D&C (4% of complete removal) not 
only in the management of AUB (without imaging 
or hysteroscopic diagnosis), but also when performed 
following hysteroscopy, with a global success rate of 
lower than 50% of procedures and a high complication 
rate [27–31]. The use of ultrasound guidance is equally of 
limited interest [32].
The gold standard, therefore, for diagnosis and 
treatment is based on hysteroscopic techniques that 
allow not only a direct visualization, but also, in some 
cases, immediate removal. This kind of hysteroscopy 
in an outpatient setting, despite being a more com-
mon procedure, is performed in fewer instances than 
the classical approach in an operating room requiring 
anesthesia and hospitalization.
Hysteroscopic polypectomy is now considered a safe 
and effective method of treatment, in part due to its 
relatively low costs and quick return to normal life 
following surgery [33–35].
In any case it is not a risk free procedure and the 
patient should be well counseled accordingly.
Narrower sized hysteroscopes now provide a greater 
opportunity to avoid hospitalization and general anes-
thesia. A large-scale class II study reported 4863 con-
secutive operative outpatient hysteroscopies including 
2306 for endometrial polyps, in which most small 
endometrial polyps were removed with minimal dis-
comfort [36]. Not only after the first diagnosis by hys-
teroscopic visualization, but also contextually, setting 
up the so-called ‘see-and-treat’ hysteroscopy. A recent 
work by Gambadauro et al. outlines a see-and-treat pol-
ypectomy as a good technique, when performed with 
a 5-French instrument, but it should consider patient’s 
pain, age and polyps dimension [37]. In selected cases, 
within an outpatient setting, the use of anesthesia such 
as paracervical block or intrauterine anesthetics may be 
considered advantageous [38].
For large diameter polyps cervical dilatation may 
be necessary requiring classical hysteroscopic resection 
with general or local anesthesia and wider diameter 
instruments.
The choice of instrument used and setting depends 
on surgeon’s experience, availability, costs, location 
and size of the polyp. Electrosurgical loops (resecto-
scopic) are effective for removing large and sessile pol-
yps with no recurrence, but with longer operating time 
and higher complication rates, whereas small forceps 
or scissors could be used when removing small pol-
yps with an operating hysteroscope; however, a 15% 
recurrence rate has been reported [33].
Bipolar Versapoint (Gynecare, NJ, USA) system, 
is an example of an additional available technique. It 
minimizes cervical dilation compared with the operat-
ing hysteroscope and the use of saline solution rather 
than glycine, with a decreased risk of hyponatremia and 
its sequelae [14,39]. Another example is the hysteroscopic 
morcellator that removes polyp chips as it resects, 
allowing continuous vision, short operating time and 
less movement of instruments through the cervix with 
a decreased potential for cervical laceration and fluid 
loss [40,41]. The availability of these techniques may be 
limited, due to their spread and costs, but there are no 
randomized control trials to prove greater effectiveness 
with regard to improve clinical outcomes.
All these procedures are uterus sparing and they 
should preserve fertility. Sometimes a more aggressive 
surgical technique may be necessary, such as endome-
trial ablation or resection, which cannot guarantee fur-
ther pregnancies. To allow these, it is also important 
to avoid uterine synechia. Intrauterine adhesions usu-
ally are caused by D&C, a technique less and less used. 
However, to our knowledge, there is not any strong evi-
dence for any therapy on preventing them, even if data 
show good results for estrogen therapy, hyaluronic acid, 
intrauterine devices or amnion graft. As this article is 
focused on surgery, and not evidence for preventing 
adhesions, we will not discuss this any further.
Adenomyosis
First described in 1860 by German pathologist Carl 
von Rokitansky, adenomyosis is a benign gynecologi-
cal disease of the uterus characterized by myometrial 
invasion by endometrial glands and stroma with deep 
abnormal growth in the muscle wall [42–45]. Adeno-
myosis could be classified into two forms: diffuse and 
localized. When the endometrial tissue in the myome-
trial thickness is well circumscribed it forms a nodule 
called adenomyoma, mostly made up of smooth mus-
cle cells, where it is often easy to recognize a wall of the 
lesion and a cleavage plane [46].
Common symptoms of adenomyosis are dysmenor-
rhea (30%), menorrhagia (50%), abnormal bleeding 
(20%) and coexisting pelvic pain (80%) [43,47–48]. A 
presumptive diagnosis based on these symptoms is 
accurate in 25% of cases, even if 30–35% of patient 
with the disease are asymptomatic [49,50]. Even if imag-
ing (transvaginal ultrasounds and MRI) can improve 
accuracy, diagnosis is based on histologic analysis 
alone. The supposed incidence varies greatly between 
5 and 70% [47,51–52] and following hysterectomies it has 
been found in 20–30% of cases [52–54].
Even if hysterectomy is still the gold standard in 
the treatment of adenomyosis, it has become necessary 
to consider conservative approaches both to maintain 
fertility and for women wishing to preserve their 
uterus.
No medical treatment allows, at the same time, 
therapy and possibility of conceiving, being all based 
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Figure 2. Adenomyomectomy procedure. (A–H) The adenomyomectomy procedure (yellow areas are the 
adenomyoma tissues). Starting from a saggital incision they perform adenomyomectomy and suture the uterus 
without entering the endometrial cavity.  
For color images please see online at www.futuremedicine.com/doi/full/10.2217/WHE.15.12  
Reproduced with permission from [56] © Elesvier (2014).
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on hormonal administration (continuous use of oral 
contraceptive pills, high-dose progestins, the levonorg-
estrel-releasing intrauterine device (LNG-IUD), dan-
azol and GnRH agonists), with consequent ovulation 
suppression.
As a result, surgery plays a significant role, even in a 
conservative scenario.
A possibility for localized adenomyosis (adenomy-
oma) is removing the lesion considering it is similar if 
not the same as a leiomyoma, even if in case of focal 
adenomyosis is more difficult to expose the lesion, 
recognize clear margins and define the exact extent 
of disease. For these reasons it could be possible that 
residual adenomyosis is left behind with subsequent 
lower effectiveness with regards to symptomatology or 
relapse. Wood [55] evaluated this kind of surgery and 
he has found an efficacy of 50%. More recent studies 
seem to confirm suboptimal results in term of symp-
toms relief (dysmenorrhea remained in 41% of patients 
and 35% reported no reduction in heavy bleeding) [56], 
but, seem to show a good trend in terms of recurrence 
rate (1% vs previous study reporting up to 69% of 
relapse) [57], and in terms of pregnancy rate after surgery 
(61.5%) [58]. All these studies differ from patient selec-
tion, surgical approach and technique, years of follow-
up and pathologist expertise, so it is difficult to make 
accurate overall evaluations. A separate consideration 
includes cystic variant of adenomyosis, typically afflict-
ing young women: the juvenile cystic adenomyoma, 
first described by Tamura et al. [59]. Takeuchi in 2010 
described a series of nine laparoscopic resection of juve-
nile cystic adenomyoma with significant improvement 
of associated dysmenorrhea and increased fertility [60].
Other conservative surgical approaches for adenomy-
osis include endometrial ablation and resection, myome-
trial electrocoagulation or reduction and uterine artery 
embolization.
Endometrial ablation or resection is surgical 
approaches used for adenomyosis in women wishing to 
preserve their uterus. These techniques are oppressed 
by high risk of failure, because it is not possible to go 
too deep on the myometrial wall, and there is a high 
risk of repeat surgery [61].
Similar to adenomyomectomy, is the endometrial 
reduction, that is performed by uterine incision and 
wedge resection removing a large part of myometrium, 
both laparoscopically and laparotomically. Literature 
shows limited number of cases, but it seems to emerge 
that the ‘H’ shape variant of the incision can give better 
results in term of pregnancy rates [62] and the removal 
as much of the adenomyotic lesion as possible, leaving 
up to 0.5 cm only of myometrium layer on both sides 
(Figure 2), seems having good outcomes [56].
Other procedures are the MR-guided focused ultra-
sound surgery (MRgFUS) and ultrasound-guided FU 
(USgFUS) [63]. A recent study confirmed good safety 
and feasibility of USgFUS with good results for both 
dysmenorrhea and menorrhagia (with significant 
reduction of bleeding at every follow-up from 1 month 
to 18 months after procedure, p < 0.001) [64].
Another procedure not recommended in women 
who wish to conceive is myometrial electrocoagulation 
due to the risk of uterine rupture for scar tissue replac-
ing adenomyosis foci [65]. Performed laparoscopically, 
even if less invasive than classical surgical myometrial 
reduction or adenomyomectomy, it is less accurate in 
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removing the lesions as it cannot be complete. There 
is a paucity of numbers of procedures in studies, but 
it has better outcome especially when associated with 
other techniques (endometrial ablation or resection and 
medical therapy) with improvement of the symptoms 
from 55 to 70% [55,65–67].
The last described procedure is uterine artery embo-
lization (UAE), typically used for the treatment of 
leiomyomas. Its role in adenomyosis treatment is con-
troversial due to frequent concomitant presence of 
myomas that reduce effectiveness of the procedure. 
When it is applied for adenomyosis alone, some stud-
ies show good outcomes. After 4.9 years 57% (of 54) 
of patients who underwent UAE reported reduction of 
bleeding; however, 19 of them (35%) relapsed [68].
Surgery for the management of adenomyosis includes 
many different alternative procedures and techniques. 
It can often be difficult for both the patient and the 
gynecologist to determine the best course of treatment. 
As result evidence-based practice should be adopted by 
gynecologists while also drawing on their own skills 
and experience to optimize patient care.
Leiomyomatosis
The most common female genital tract benign tumors 
are uterine myomas. It is estimated that 20–30% 
of reproductive aged women are affected by this 
disease [69] and it increases to 70% in 49-year-old 
women [70].
Symptoms are present in about 30% of patients 
and they manifest as AUB, subfertility, recurrent 
miscarriage and urinary frequency [71].
Traditionally the management of this disease is 
based on surgery (hysterectomy and myomectomy), 
although medical options are considered useful and 
effective as both progesterone and estrogen receptors 
can be present in myomas [72].
In 1999 leiomyomatosis was the surgical indication 
for 33% of hysterectomies performed in the USA, but 
nowadays in the last two decades this trend is changing, 
with an increase in more conservative approaches. Par-
ticularly myomectomy is the only surgical technique 
that allows fertility sparing, even if is still not very 
clear the effectiveness of the procedure in improving 
fertility and pregnancy outcome [73,74]. Most women 
ask to preserve uterus since they have not completed 
childbearing, which occurs in older age than before 
for social and economic reasons and thanks to oocyte 
donation as well. Not only women wishing pregnancy 
ask to maintain uterus, but they could ask it for per-
sonal reasons as well (worried for their sexual life and 
their femininity [75]).
Usually the indications for myomectomy are serious 
medical condition due to heavy bleeding with severe 
anemia and ureteral obstruction. In some cases myo-
mectomy is requested also for AUB only, or a poorer 
quality of life for incontinence, urinary frequency, 
pelvic pain or pressure.
Uterine leiomyomatosis represents the L in the 
PALM-COEIN system, and this entity is subdi-
vided into SM (submucousal) or O (other) and SM, 
itself, has a subclassification originally proposed by 
Wamsteker et al. [76] on the basis of endometrial cavity 
distortion (Figure 3).
The other myomas (IM and SS [intramural and sub-
serosal, respectively] ones), especially when endome-
trial cavity is of a normal size, should not cause a lot of 
symptoms and their removal seems to be not effective 
on fertility improvement.
Actually the only submucousal myomas are involved 
in AUB and subfertility with higher likelihood, even if 
a 2012 Cochrane meta-analysis of literature showed no 
evidence for myomectomy (even of submucousal ones) 
in improving fertility [77].
An important message to give to the patient is 
the very low likelihood of a malign degeneration of 
the myomas. Leiomyosarcomas have low incidence 
(0.23%) and usually are a de novo transformation and 
are more frequent in postmenopausal age [78]. Given 
this benign natural history of myomas it could be pos-
sible to make the subsequent considerations about their 
management, even an attendant or medical one.
Hysteroscopic myomectomy is the least invasive 
approach currently available to treat submucousal myo-
mas with good results [79–81]. The size of the myomas is 
the first limiting factor for a single myomectomy pro-
cedure, while intramural extension seems to be more 
difficult with a greater risk of complications [82,83].
Usually a myoma bigger than 5–6 cm is considered 
not eligible for hysteroscopic myomectomy. A recent 
study [84] confirmed this limit, suggesting that till 5 cm 
of diameter of submucousal myoma, hysteroscopic 
resection should be the first choice in case of AUB.
Indeed AUB symptoms find good relief by this kind 
of procedure and most of the studies show an effec-
tiveness from 70 to 99% [85], but long term follow-
ups show an increase of recurrences (probably due to 
incomplete removal and other functional bleedings) 
and the need of a second surgery.
A particularly hostile localization of SM is the 
lower uterine segment with extension to the cervix. 
These lesions could find an alternative option in the 
vaginal myomectomy described in a report published 
by Goldrath [86].
The management concerning intramural and sub-
serosal myomas is essentially based on laparoscopic or 
abdominal myomectomy (LM and AM), but often this 
kind of lesions are not cause of AUB.
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Figure 3. International Federation of Gynecology and Obstetrics classification of myomas. 
Reproduced with permission from [4] © Elsevier (2014).
Leiomyoma
subclassication
system
2-5
6
5
7
2
1
43
0
0 Pedunculated intracavitary
<50% intramural
≥50% intramural
Contacts endometrium; 100% intramural
Intramural
Subserosal ≥50% intramural
Subserosal <50% intramural
Subserosal pedunculated
Other (specify e.g., cervical, parasitic)
Submucosal and subserosal, each with less
than half the diameter in the endometrial
and peritoneal cavities, respectively
SM – submucosal
O – other
Hybrid
leiomyomas
(impact both
endometrium 
and serosa)
1
2
3
4
5
6
7
8
2-5
Two numbers are listed separated by a hyphen. By 
convention, the rst refers to the relationship with the 
endometrium while the second refers to the relationship 
to the serosa. One example is below
future science group
Review    Finco, Centini, Lazzeri & Zupi
Many studies tried to point out a definitive 
approach, but till now it seems an open issue. Prob-
ably the best way to give a right counseling to the 
patients is to propose the best alternatives by choos-
ing a technique that could offer a good success, with 
the minor risk and pain, and what surgeons have 
available and are able to do. In terms of AUB con-
trol neither laparoscopic myomectomy nor abdominal 
(minilaparotomic one as well) has shown clear advan-
tages in term of primary outcomes (fertility or con-
trol of bleeding), but it is well known that the minor 
invasivity of the laparoscopic approach even if some 
studies seem to suggest a better outcome for fertile 
patients that underwent to LM for symptomatic leio-
myomas [87]. LM has demonstrated a minor operative 
blood loss, less haemoglobin loss, more rapid hospital 
discharge, reduced postoperative pain and less over-
all complications (with a similar incidence of major 
complications and recurrence rate) [88,89]. Recently 
the procedure has been put under strict control due to 
the US FDA’s statement [90] due to the risk of diffu-
sion of leiomyosarcoma related to the use of ‘power’ or 
electromechanical morcellation during laparoscopical 
myomectomies (and laparoscopical supracervical hys-
terectomy [LSH]), but we think that, if the patient is 
well evaluated and the surgeon has high skill in the 
procedure, advantages of this approach could still be 
greater than this low risk or, if possible, the trans-
vaginal extraction of the myoma is a quick and safe 
alternative [91].
Another technique that has not been well studied 
is vaginal myomectomy. A recent literature review 
showed good results, comparable with those from LM 
or AM. It is difficult to assess the exact role of the vagi-
nal approach, due to the lack of data, but many authors 
suggest to confine it for myomas not bigger than 8 cm 
and localized only on the posterior uterine wall [92].
Directly related to the AUB symptomatology and 
the choice of the surgical ways the literature tried to 
investigate the opportunity of a preoperative GnRHa 
administration. A Cochrane meta-analysis [93] and a 
more recent review [94] stated that GnRHa pretreat-
ment does not advantage in terms of operative times 
in LM, despite myoma shrinkage, due to the greater 
difficulty to recognize the cleavage plane. However 
the same review demonstrated a further reduction of 
intraoperative bleeding and increased postoperative 
hemoglobin concentration in patients undergoing LM. 
Another preoperative drug administration recently 
proposed prior to myomectomy is a daily regimen of 
selective progesterone-receptor modulators. Two stud-
ies compared ulipristal acetate (UPA) with placebo [95] 
and with leuprolide [96] acetate (GnRHa) for the treat-
ment of symptomatic uterine fibroids before surgery. 
Both studies showed good results on controlling bleed-
ing, reducing size of fibroids and with low rate of hot 
flashes (in comparison with GnRHa administration). 
Further studies are needed to evaluate the role of UPA 
before surgery, or to delay it or even to avoid it. Since 
UPA showed good results, it could be possible, as 
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already suggested [97], that fibroids management could 
change in the next few years and more data are needed 
to asses the role of UPA to avoid recurrences.
The new entrance of robotic assisted laparoscopies 
till now has not demonstrated benefits in comparison 
with LM and its use appears to be not justifiable [98] , 
even if the hypothesis was a better uterine suture and a 
lower risk of scar rupture during pregnancy (1% risk of 
uterine rupture in pregnancy after LM [99]). That is the 
reason why many surgeons propose caesarean section 
for pregnancies after myomectomy (both LM or AM).
The real incidence of uterine rupture after lapa-
roscopic myomectomy seems to be not necessarily 
greater than the abdominal one, but needs more data 
to be evaluated. Two recent reviews [100,101] of litera-
ture suggest no increased risk of uterine rupture after 
laparoscopic myomectomy and, even if evidences are 
poor due to the low rate of incidence, many authors 
suggest to limit electrosurgery coagulation during the 
procedure to reduce that risk and to do a multiple layer 
uterine closure.
Likely for adenomyosis, also leiomyomatosis could 
find benefits by alternative approaches to traditional 
surgery. One of the most investigated is the UAE. In 
2012 the Cochrane Library [102] published a meta-
analysis on this issue and it confirmed a good patient 
satisfaction and less hospital stay and quicker return 
to normal life in comparison of any type of surgery. 
On the other side, UAE seems to have a higher risk of 
minor complications and higher rate of further surgery 
within 2–5 years from the first procedure and, since it 
may be associated with a higher risk of preterm labor, 
intrauterine growth restriction and postpartum hemor-
rhage, it should be carefully suggested in patients with 
future pregnancy desire. Similar results come from 
localized uterine artery occlusion [103,104], both with 
electrodessication or clips managed laparoscopically 
and with coils deposited in the uterine artery [105].
Other procedures less common and not yet stan-
dardized include leiomyoma ablation or myolysis, 
hypothermic ablation, hyperthermic ablation by laser 
and radiofrequency electrical energy (Nd:YAG or RF) 
and ablation by focused ultrasound energy (HIFU). 
Myolisis appears to be a feasible alternative [106], but all 
these techniques need more study and analysis. RMg-
FUS is the best investigated and its clinical results are 
promising [107] but it is needed a good patient selection 
and large scale clinical trials for a better comparison 
with the others techniques [108].
Even if the role of myomas in fertility is still unclear 
(especially for the IM and SS ones), surgery is often 
performed when there is no other evident cause of 
sterility, so it is important to develop not only a uterus-
preserving technique, but also a fertility-improving 
approach. Always keeping in mind fertility desire and 
outcome after surgery, myomectomy seems to be the 
best choice, also compared with UAE [102] showing 
statistically significant (p < 0.05) differences on preg-
nancy rate of 50 versus 78%, delivery rate of 19 versus 
48% and miscarriage rate of 53 versus 23%, after UAE 
and after myomectomy, respectively.
Malignancy
The last letter of the ‘PALM’ acronym stays for ‘Malig-
nancy,’ meaning AUB caused by endometrial transfor-
mation toward cancer or precancer lesion. This entity 
is less common in reproductive age women than older 
ones, but it should always be considered, even if it was 
to rule it out.
Endometrial carcinoma (endometrioid type par-
ticularly) and its precursors are characterized by an 
hyper/relative estrogen ambient with consequent endo-
metrial stimulation to proliferation of glandes and epi-
thelial changes. So it explains the common symptom 
of AUB in these cases.
Sampling of endometrial tissue is an important 
approach in fertile age women with AUB. Although 
endometrial malignancy is found rarely among fertile 
age women with AUB, it must be excluded prior to any 
surgical intervention
One of the best goals of clinicians and pathologists 
is to recognize the lesion as soon as possible, with an 
early diagnosis of precancer lesions. These are usually 
grouped on the basis of Kurman’s classification [109] 
and called ‘atypical endometrial hyperplasia’ (AEH) 
to which, recently, has been added a new quantita-
tive classification [110] that calls the cancer precursor: 
‘endometrial intraepithelial neoplasia’ (EIN). The 
first study is at the basis of the 1994 4-Class WHO 
schema [111] and it recognizes the well known four cat-
egories on the evaluation of nuclear atypia and glan-
dular complexity: simple hyperplasia, complex hyper-
plasia, simple hyperplasia with atypia and complex 
hyperplasia with atypia, but they badly correlate with 
clinical management.
The other schema has been developed by the Inter-
national Endometrial Collaborative Group. This one 
seems being a better outcome predictor, better interob-
server reproduced [112]. Even if both the diagnosis of 
EIN [113] and atypical hyperplasia [114] have positive 
predictive value [115], the NIH recommends EIN as a 
better schema, appearing to be better tailored on dis-
tinguishing between premalignant lesions and which 
are not [116].
In case of suspecting AEH/EIN, surgery has the first 
role to make the diagnosis, by sampling the endometrial 
tissue. This is possible by both curettage and biopsy but 
both are not able to reach the goal of excluding any like-
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lihood of cancer, due to their inability to make a wide 
and satisfactory enough sampling of the cavity [117]. 
This could be less important in those cases where hys-
terectomy has already previewed in the management, 
that can not be the routine in fertile women.
For women wishing to preserve uterus surgery has 
quite no place as endometrial ablation could not be 
acceptable, while medical treatment (local or systemic 
progestin administration) has a role if the patient is 
kept under strict surveillance [116].
Otherwise total hysterectomy (with or without 
bilateral salpingo-oophorectomy) is the gold standard 
in treatment of AEH/EIN being curative, effective 
and provides a definitive diagnosis. Supracervical hys-
terectomy (both laparotomic and laparoscopic) is not 
recommended [118].
Furthermore all the lesions discussed above (PAL) 
could have their malignant (or premalignant) equiva-
lent. In these cases it is evident how important is the 
answer of the anatomopathologist to the tissue sample 
coming from the first surgery. As for AEH/EIN or 
endometrial cancer, also for the other malignant lesion 
total (or radical) hysterectomy is the only surgical 
approach.
COEIN
All the diseases causing AUB included in the second 
part of the PALM-COEIN system are usually not asso-
ciated to organic or structural entities, so surgery could 
be less effective or, at least, not the first choice in the 
management.
Cases where medical treatment has failed and/or are 
not eligible for that could benefit of a surgical approach.
Endometrial ablation or resection is indicated for 
women wishing to preserve their uterus, but not wish-
ing to bear children. There are several techniques such 
as global ablation, rollerball resection or yttrium alu-
minum garnet laser (Nd:YAG). As is intuitive, the 
deeper the lesions within the myometrial wall, the 
poorer the success of the rollerball resection, as dem-
onstrated in two studies [55,119]. This is because it is 
not possible to resect deeper than 3 mm, as an arte-
rial layer lies around 5 mm under the myometrial sur-
face [55]. Also global endometrial ablation (both with 
thermal balloon and radiofrequency ablation) shows 
poor results with high risk of failure and repeat surgery 
(second ablation or hysterectomy) [61].
We think that, when it is not possible to preserve 
the uterus and/or where there is no pregnancy desire, 
hysterectomy is the best procedure, being definitive 
and curative. In particular, the laparoscopic approach 
allows a minimally invasive surgery, with low risk of 
complications and no risk of recurrence and no further 
surgery.
Hysterectomy
Hysterectomy represents the most common gynecologi-
cal procedure in the world and a third of 60-year-old 
women underwent this surgery [120].
Its effectiveness in improving AUB symptoms, being 
curative and definitive, is well recognized.
Even if it is the most common gynecologic surgical 
procedure, it still has, as any kind of surgery, some com-
plications, that lessen as surgeon experience increases. 
Those complications are: hemorrhage, infection, throm-
boembolism, injury to viscera and neuropathy. Their 
incidence ranges depending on the type of hysterectomy, 
surgeon’s skill and study design.
Nowadays the debate is oriented on the comparison 
between it and the other less invasive procedures and, 
inside hysterectomies, between the different approaches 
available (open surgery, vaginal and laparoscopic and 
total [TLH] or supracervical ones).
Literature shows a lot of reviews and meta-analysis on 
that, but there is not a definitive answer, because clinical 
practice meets real patients and not only the theoretical 
ones and each one of them needs a personal counseling 
and the best fitted approach.
Hysterectomy is considered highly costly at the begin-
ning, but has low cost later on, while other treatments 
have low primary costs, but they could be much more 
expensive in the long run if they had not resolved the 
problem. Unlikely there are few studies analyzing the 
cost–effectiveness of hysterectomies and those doing 
it are difficult to compare each other with no strong 
evidences [121].
A Cochrane Library publication tried, in 2009, to 
compare the different approaches of hysterectomies. In 
its conclusions the authors evidenced vaginal hysterec-
tomy (VH) as the first choice, before laparoscopic hys-
terectomy (TLH) and, third, abdominal hysterectomy 
(AH), as there were no differences in term of outcomes, 
but just in recovery times and costs. At the end, they 
underlined the importance of the woman’s choice, dis-
cussed with her surgeon [122]. Same conclusions reached 
Johnson in 2005, suggesting that, when VH is not 
possible, the second choice is LH even if, according to 
their analysis, it has greater risk of bladder and ureter 
injury [123]. Always on the same direction goes a recent 
meta-analysis that compares VH versus laparoscopically 
assisted vaginal hysterectomy. It shows no statistical dif-
ferences in complications, conversion rate, hospital stay, 
blood loss, duration of paralytic ileus and weight of the 
surgically treated uterus and just a shorter operative time 
for VH [124].
Another Cochrane has compared with tal hysterecto-
mies (TLH) versus subtotal ones (LSH; both laparotomic 
and laparoscopic), finding no differences between the 
two procedures [125]. On the other side, laparoscopically 
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assisted vaginal hysterectomy shows lower early postoper-
ative pain scores and complication rates when compared 
with minilaparotomic hysterectomy [126].
An open issue remains the comparison between LSH, 
as the less invasive laparoscopical approach, and the 
two other mini-invasive procedures: TLH and VH. A 
recently published work evidences as LSH meets high 
patient’s satisfaction and reduces cyclic pelvic pain [127].
Also when compared with the less-invasive options 
of endometrial ablation, levonorgestrel intrauterine sys-
tem (LNG-IUS), and medications, no one can strongly 
assure to become the gold standard in AUB treatment, 
but everything is a tradeoff between effectiveness and 
risks [128].
Expert commentary
The modern trend in approaching AUB is related to 
the reduction of the global number of hysterectomies. 
A conservative surgical management of this common 
symptom is mandatory independently from the need of 
pregnancies. Conservative endoscopic surgery and medi-
cal treatment of AUB are now facilitated by the use of 
the PALM-COEIN classification. The knowledge of 
different causes (organic or not) of AUB consents a more 
flexible and tailored approach to the disease.
Conclusion
Surgical management of AUB is challenging both for 
women and physicians. New medical treatments are 
always flanked by new surgical and alternatives tech-
niques. The best way to counsel the patient that is neces-
sary to tailor the treatment is to listen to the woman, to 
her needs and her wishes and to offer an up-to-date view 
of the state of the art. 
Future perspective
The number of surgical and medical strategies is increas-
ing and it is not easy to choose among a big offer, both 
for the patient, and for the doctor. Many factors have 
to be considered and more awareness is due. Since preg-
nancy desire is being always more and more scheduled 
and planned, maternal age is growing and, with it, the 
importance of the best choice of a tailored therapy to 
treat AUB in fertile age. In the future all the minimally 
invasive procedures will replace the actual common 
definitive approach. New technologies as robotics or new 
targeted drug development will consent this evolution 
in treating abnormal uterine bleeding. This could mini-
mize operative time and costs, and increasing patients 
satisfaction.
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Executive summary
•	 Abnormal uterine bleeding is the most common gynecological disease and its etiology is classified by the 
2011’s PALM-COEIN system.
•	 The best treatment for endometrial polyps is hysteroscopic resection and, where possible this can be 
performed in an outpatient setting. Dilatation and curettage should be avoided.
•	 The gold standard for the treatment of adenomyosis is hysterectomy, but local resection and removal have 
good results as new minimally invasive techniques, even if more clinical trails are necessary to further evaluate 
procedures and outcomes.
•	 Leiomyomatosis is symptomatic mostly due to submucousal myomas which could be removed by hysteroscopic 
resection if <5–6 cm diameter.
•	 Conservative surgery in the management of endometrial premalignant lesion is quite limited, as their 
treatment is medical or definitive (total hysterectomy).
•	 Hysterectomy is the definitive treatment of abnormal uterine bleeding and it should be performed by 
vaginal or laparoscopic route and, if possible, it should be considered laparoscopic supracervical one, being a 
minivasive and well perceived technique.
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